UBS Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

UBS Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,300	Closed	-$581K	–	8105
2016 Q3	$581K	Buy	+8,300	New	+$460K	﹤0.01%	3815

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

UBS Group's EGRX Position: Q4 2024 in Review

UBS Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 480 shares — an estimated $1.79K sold.

UBS Group first reported a position in EGRX in Q2 2015 and held it in 38 quarters. The position peaked at $3.27M in Q4 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

UBS Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
UBS Group sold 480 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $1.79K.
UBS Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 38 quarters.
UBS Group's Eagle Pharmaceuticals, Inc. position peaked at $3.27M in Q4 2018.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.